Today's Top Health Care Stocks to Watch: Celgene Corporation and Sarepta Therapeutics, Inc.

Today's top stories in health care and biotech.

May 22, 2014 at 8:55AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corp. (NASDAQ:CELG) and Sarepta Therapeutics (NASDAQ:SRPT)

Celgene announces changes to its leadership team
One of biotech's top names announced major changes to its executive management this morning, promoting three individuals internally and hiring a new Executive Vice President/CFO from outside of the company. Specifically, Mark Alles is being promoted to President/COO, Jacqualyn Fouse is being promoted to President of Hematology and Oncology, and Scott Smith will become the President of Inflammation & Immunology. In a noteworthy move, Celgene reached out to one of Biogen and Merck & Co.'s former executives in Peter Kellogg to become the new Vice President and CFO. All leadership changes will become effective August 1, 2014.  

These leadership changes are certainly intriguing given that they are coming on the back of the first step in defending Revlimid's patent protection. As a refresher, Revlimid's patents are being challenged by competitors hoping to develop a generic version of the blockbuster cancer drug. A Markman hearing was held last week, with most observers reporting that Celgene's attorneys seemed to hold the upper hand.

Looking ahead, we will need to wait and see what this managerial shakeup ultimately means for this leading biotech. My off the cuff view is that the internal promotions are rewards for the series of clinical and commercial successes the company has achieved in recent years. As such, the key hire to watch will probably be Peter Kellogg, who brings decades of experience to this position. 

Sarepta could move higher after positive mention
Shares of Sarepta Therapeutics are up 4% in premarket trading this morning after Roth Capital initiated coverage on the stock, rating it a "buy". Even more intriguing, however, is the $52 price target the company placed on Sarepta shares. All else being equal, Roth is suggesting that Sarepta is worth around $3 billion in terms of its market cap, without an approved product. 

What's my take? My view is that Roth is looking backwards at how Sarepta's shares performed last year before the company's experimental Duchenne muscular dystrophy therapy eteplirsen ran into regulatory issues with the Food and Drug Administration. Now that those issues are being worked through, Roth appears to expect Sarepta shares to move closer to their previous 52-week highs.

While that is certainly possible, it's important to remember that we are also in the midst of a radically different market environment than last year. Clinical-stage biotechs have been some of the worst performers this year, as sentiment has shifted more toward valuations based on cash flows and revenue streams. Moreover, Sarepta was undoubtedly a beneficiary of this rising tide among all biotechs last year. And now that developmental biotechs have come back down to Earth to some degree, it might be difficult for Sarepta to achieve similar levels of performance prior to a regulatory approval for its lead clinical candidate. As always, time will tell!   

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


George Budwell has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information